Retinopathy and hypertension affect serum high-sensitivity C-reactive protein levels in Type 2 diabetic patients

Journal of Diabetes and its Complications

Volumn 19, Issue 3, 2005, Pages 123-127

  Tsunoda, Keiko ^a   Arita, Mikio ^a   Yukawa, Mariko ^b   Ueyama, Minoru ^b   Furuta, MacHi ^a   Nakagawa, Takayuki ^a   Nanjo, Kishio ^a   Sanke, Tokio ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

High sensitivity C reactive protein; Hypertension; Retinopathy; Type 2 diabetes mellitus

Indexed keywords

ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD ANALYSIS; BODY MASS; CARDIOVASCULAR RISK; CLINICAL EXAMINATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 18144368552     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2004.08.001     Document Type: Article

References (27)

1. M.A. Albert, E. Daielson, N. Rifai, P.M. Ridker PRINCE Investigator Effect of statin therapy on C-reactive protein levels. The Pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study JAMA 286 2001 64 70
2. J.I. Barzilay, L. Abraham, S.R. Heckbert, M. Cushman, L.H. Kuller, H.E. Resnick, and R.P. Tracy The relation of markers of inflammation to the development of glucose disorders in elderly. The cardiovascular heart study Diabetes 50 2001 2384 2389
3. E. Bertin, P. Nguyen, M. Guenounou, V. Durlach, G. Potron, and I. Leutenegger Plasma level of tumor necrosis factor-alpha (TNF-α) are essentially dependent on visceral fat amount in type 2 diabetic patients Diabetes & Metabolism 26 2000 178 182
4. K. Chul Sung, J.Y. Suh, J.H. Kim, J.H. Kang, H. Kim, M.H. Lee, J.R. Park, and S.W. Kim High sensitivity c-reactive protein as an independent risk factor for essential hypertension American Journal of Hypertension 16 2003 429 433
5. C.J.M. Doggen, R.J. Berckmans, A. Sturk, C.V. Manger, and F.R. Rosendaal C-reactive protein. Cardiovascular risk factors and the association with myocardial infarction in men Journal of Internal Medicine 248 2000 406 414
6. A. Festa, R. D'Agostino, G. Howard, L. Mykkanen, R.P. Tracy, and S.M. Haffner Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the insulin resistance atherosclerosis study Kidney International 58 2000 1703 1710
7. E.S. Ford Body mass index, diabetes, and C-reactive protein among US adults Diabetes Care 22 1999 1971 1977
8. D.J. Freeman, J. Norrie, M.J. Caslake, A. Gaw, I. Ford, G.D.O. Lowe, D.S.T. O'Reilly, C.J. Packard, N. Sattar West of Scotland Coronary Prevention Study Group C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study Diabetes 51 2002 1596 1600
9. M. Frohlich, H. Boeing, A. Imhof, R. Muche, G. Berg, H. Brenner, W.L. Hutchinson, W. Koenig, and M.P. Pepys Association between C-reactive protein and features of the metabolic syndrome Diabetes Care 23 2000 1835 1839
10. B.D. Horne, J.B. Muhlestein, J.F. Carlquist, T.L. Bair, T.E. Madsen, N.I. Hart, and J.L. Anderson Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease Journal of the American College of Cardiology 36 2000 1774 1780
11. C.B. Kathryn, D.J. Edward, M.S. Nelson, T.H. Lam, C.F. Sidney, and S.L. Karen C-reactive protein predicts the deterioration of glycemia in Chinese subjects with impaired glucose tolerance Diabetes Care 26 2003 2323 2328
12. E.S. Kilpatrick, B.G. Keevil, C. Jagger, R.J. Spooner, and M. Small Determinants of raised C-reactive protein concentration in type 1 diabetes Quarterly Journal of Medicine 93 2000 231 236
13. I.T. Lee, W.H. Sheu, S.Y. Lin, W.J. Lee, Y.M. Song, and H.C. Liu Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetes with hyperlipidemia Journal of Diabetes and its Complications 16 2002 382 385
14. J.F. Navarro, C. Mora, M. Maca, and J. Garca Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus American Journal of Kidney Diseases 42 2003 53 61
15. T.A. Pearson, G.A. Mensah, R.W. Alexander, J.L. Anderson, R.O. Cannon, M. Criqui, Y.Y. Fadl, S.P. Fortman, Y. Hong, G.L. Myers, N. Rifai, S.C. Smith, K. Taubert, R.P. Tracy, and F. Vinicor Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 2003 499 511
16. P.M. Ridker, R.J. Glynn, and C.H. Hennekens C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction Circulation 97 1998 2007 2011
17. P.M. Ridker, C.H. Hennekens, J.E. Buring, and N. Rifai C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women New England Journal of Medicine 342 2000 836 843
18. P.M. Ridker, N. Rifai, and S.P. Lowenthal Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hyperclolesterolemia Circulation 103 2001 1191 1193
19. N. Rifai, and P.M. Ridker High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease Clinical Chemistry 47 2001 403 411
20. N. Rifai, R.P. Tracy, and P.M. Ridker Clinical efficacy of an automated high-sensitivity C-reactive protein assay Clinical Chemistry 45 1999 2136 2141
21. R. Ross Atherosclerosis: an inflammatory disease N Engl J Med 340 1999 115 126
22. K.C. Tan, W.S. Chow, S.C. Tam, V.H. Ai, C.H. Lam, and K.S. Lam Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilatation in type 2 diabetes mellitus Journal of Clinical Endocrinology and Metabolism 87 2002 563 568
23. M. Tominaga Proposal from a study of diabetes mellitus prevalence survey in Funagato Town Diabetic Complications 14 2000 92 93
24. M. Tominaga, H. Eguchi, H. Manaka, K. Igarashi, T. Kato, and A. Sekikawa Impaired glucose tolerance is a risk factor for cardiovascular disease, but not inpaired fasting glucose. The Funagata Diabetes Study Diabetes Care 22 1999 920 924
25. R.P. Tracy Inflammation in cardiovascular disease Circulation 97 1998 2000 2002
26. M.A. van de Ree, M.V. Huisman, H.M. Princen, A.E. Meinders, and C. Kluft Strong decrease of high sensitive C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes Atherosclerosis 166 2003 129 135
27. M. Visser, L.M. Bouter, G. McQuillan, M.H. Wener, and T.B. Harris Elevated C-reactive protein levels in overweight and obese adults JAMA 282 1999 2131 2135